Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies

[1]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[2]  G. Gibson,et al.  Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes , 2013, Molecular and Cellular Neuroscience.

[3]  G. Mead,et al.  Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.

[4]  B. Xiang,et al.  Pancreatic islet cell autophagy during aging in rats. , 2013, Clinical and investigative medicine. Medecine clinique et experimentale.

[5]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[6]  Xuefeng Yu,et al.  Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. , 2012, Journal of Alzheimer's disease : JAD.

[7]  R. Castellani,et al.  Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.

[8]  T. Abbruscato,et al.  The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer’s Disease , 2012, International journal of molecular sciences.

[9]  Bojana Stefanovic,et al.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. , 2012, Brain : a journal of neurology.

[10]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[11]  Bill Wilson,et al.  Intensity of dementia through latent variable modelling (I-DeLV) in the AIBL cohort , 2012, Alzheimer's & Dementia.

[12]  M. Goedert,et al.  Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy , 2012, Brain : a journal of neurology.

[13]  Bin Zhao,et al.  Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease? , 2012, Journal of neuroscience research.

[14]  David H Rowitch,et al.  Astrocytes and disease: a neurodevelopmental perspective. , 2012, Genes & development.

[15]  J. Fine,et al.  Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice , 2012, Experimental Brain Research.

[16]  H. Rosenmann.  CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease , 2012, Journal of Molecular Neuroscience.

[17]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[18]  D. Munoz,et al.  An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. , 2012, The Journal of clinical investigation.

[19]  Paula I. Moreira,et al.  Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation , 2012, Brain Research.

[20]  E. Feldman,et al.  Insulin resistance in the nervous system , 2012, Trends in Endocrinology & Metabolism.

[21]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[22]  M. Murphy,et al.  β-Secretases, Alzheimer's Disease, and Down Syndrome , 2012, Current gerontology and geriatrics research.

[23]  P. Moreira,et al.  Insulin in Central Nervous System: More than Just a Peripheral Hormone , 2012, Journal of aging research.

[24]  I. Harman-boehm,et al.  Effect of intranasal insulin on cognitive function: a systematic review. , 2012, The Journal of clinical endocrinology and metabolism.

[25]  C. Hölscher,et al.  Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice , 2012, Neurobiology of Aging.

[26]  J. Fine,et al.  Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice , 2012, Drug Delivery and Translational Research.

[27]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[28]  Hsinyu Lee,et al.  Autophagy: A double-edged sword in Alzheimer’s disease , 2012, Journal of Biosciences.

[29]  S. M. de la Monte.  Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012, Current Alzheimer research.

[30]  Samantha J. Brooks,et al.  Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions , 2011, Molecular Neurobiology.

[31]  M. Sabbagh,et al.  Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer’s Disease , 2011, Current neuropharmacology.

[32]  F. Gage,et al.  Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb , 2011, EMBO molecular medicine.

[33]  Christos Davatzikos,et al.  Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals , 2011, Neurobiology of Aging.

[34]  G. Ricevuti,et al.  Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. , 2011, Autoimmunity reviews.

[35]  I. Mook‐Jung,et al.  Insulin Resistance and Alzheimer’s Disease , 2011 .

[36]  Sarah A. Chau,et al.  Current and Emerging Drug Treatment Options for Alzheimer’s Disease , 2011, Drugs.

[37]  E. McNay,et al.  Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes , 2011, Neurobiology of Learning and Memory.

[38]  Ying Liu,et al.  Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes , 2011, The Journal of pathology.

[39]  Arturo Pujia,et al.  Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis , 2011, Journal of cellular and molecular medicine.

[40]  H. Soininen,et al.  AMP‐activated protein kinase: a potential player in Alzheimer’s disease , 2011, Journal of neurochemistry.

[41]  Marta Martínez-Vicente,et al.  Fighting neurodegeneration with rapamycin: mechanistic insights , 2011, Nature Reviews Neuroscience.

[42]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[43]  L. Gravitz.  Drugs: A tangled web of targets , 2011, Nature.

[44]  P. Dolan,et al.  The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics , 2011, Journal of cellular and molecular medicine.

[45]  A. Tylicki,et al.  [Thiamine and its derivatives in the regulation of cell metabolism]. , 2011, Postepy higieny i medycyny doswiadczalnej.

[46]  K. Niswender.  Basal Insulin: Beyond Glycemia , 2011, Postgraduate medicine.

[47]  N. Marchionni,et al.  Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities , 2011, Experimental diabetes research.

[48]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[49]  M. Nakazato.  [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[50]  C. Zhong,et al.  Exposure to Pyrithiamine Increases β-Amyloid Accumulation, Tau Hyperphosphorylation, and Glycogen Synthase Kinase-3 Activity in the Brain , 2011, Neurotoxicity Research.

[51]  C. Hölscher,et al.  Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain , 2011, Journal of neuroscience research.

[52]  D. Turner,et al.  Age-Induced Alterations in Hippocampal Function and Metabolism. , 2011, Aging and disease.

[53]  G. Schellenberg,et al.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease , 2011, Neurobiology of Aging.

[54]  A. Hazell,et al.  Modeling neurodegenerative disease pathophysiology in thiamine deficiency: Consequences of impaired oxidative metabolism , 2011, Neurochemistry International.

[55]  A. Sun,et al.  Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides , 2011, Neurobiology of Aging.

[56]  Huaxi Xu,et al.  APP processing in Alzheimer's disease , 2011, Molecular Brain.

[57]  R. Uranga,et al.  Iron and Mechanisms of Neurotoxicity , 2010, International journal of Alzheimer's disease.

[58]  T. Iwatsubo,et al.  Efficient four‐drug cocktail therapy targeting amyloid‐β peptide for Alzheimer's disease , 2010, Journal of neuroscience research.

[59]  I. Gozes.  Tau pathology and future therapeutics. , 2010, Current Alzheimer research.

[60]  F. LaFerla,et al.  Formulation of a Medical Food Cocktail for Alzheimer's Disease: Beneficial Effects on Cognition and Neuropathology in a Mouse Model of the Disease , 2010, PloS one.

[61]  C. Hölscher,et al.  Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats , 2010, Neuroscience.

[62]  Karl Herholz,et al.  Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease , 2010, Expert review of neurotherapeutics.

[63]  Eva L. Feldman,et al.  How does diabetes accelerate Alzheimer disease pathology? , 2010, Nature Reviews Neurology.

[64]  Y. Reijmer,et al.  Cognitive dysfunction in patients with type 2 diabetes , 2010, Diabetes/metabolism research and reviews.

[65]  J. Born,et al.  Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. , 2010, The Journal of clinical endocrinology and metabolism.

[66]  G. Münch,et al.  Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer’s disease? , 2010, Experimental Gerontology.

[67]  I. Ferreira,et al.  Multiple Defects in Energy Metabolism in Alzheimers Disease , 2010 .

[68]  R. V. Van Heertum,et al.  Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls , 2010, Journal of geriatric psychiatry and neurology.

[69]  Hyoung-Gon Lee,et al.  Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease , 2010, International journal of biomedical science : IJBS.

[70]  M. Valko,et al.  Metals, oxidative stress and neurodegenerative disorders , 2010, Molecular and Cellular Biochemistry.

[71]  Michael Gold,et al.  Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2010, Dementia and Geriatric Cognitive Disorders.

[72]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[73]  J. García-Lara,et al.  The metabolic syndrome, diabetes, and Alzheimer's disease. , 2010, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[74]  E. Masliah,et al.  Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex , 2010, PloS one.

[75]  G. Halliday,et al.  Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease , 2010, Neuropathology and applied neurobiology.

[76]  Tian-Le Xu,et al.  Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. , 2010, Brain : a journal of neurology.

[77]  T. Sobow.  Combination treatments in Alzheimer’s disease: risks and benefits , 2010, Expert review of neurotherapeutics.

[78]  E. Carro,et al.  A New Tacrine–Melatonin Hybrid Reduces Amyloid Burden and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease , 2010, Neurotoxicity Research.

[79]  N. Bazan,et al.  Inflammatory, Apoptotic, and Survival Gene Signaling in Alzheimer’s Disease , 2010, Molecular Neurobiology.

[80]  Ivan J. Perry,et al.  A Prospective Analysis of Elevated Fasting Glucose Levels and Cognitive Function in Older People , 2010, Diabetes.

[81]  W. Frey,et al.  Intranasal delivery to the central nervous system: mechanisms and experimental considerations. , 2010, Journal of pharmaceutical sciences.

[82]  B. Yankner,et al.  Neural mechanisms of ageing and cognitive decline , 2010, Nature.

[83]  L. Mosconi,et al.  Early Detection of Alzheimer’s Disease with PET Imaging , 2010, Neurodegenerative Diseases.

[84]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[85]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[86]  L H Kuller,et al.  Age, Alzheimer disease, and brain structure , 2009, Neurology.

[87]  C. Antke,et al.  In vivo imaging of synaptic function in the central nervous system I. Movement disorders and dementia , 2009, Behavioural Brain Research.

[88]  P. Moreira,et al.  Mitochondria as a therapeutic target in Alzheimer's disease and diabetes. , 2009, CNS & neurological disorders drug targets.

[89]  E. Mandelkow,et al.  Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. , 2009, Human molecular genetics.

[90]  Yanling Zhao,et al.  Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency , 2009, Journal of neurochemistry.

[91]  M. Beal,et al.  Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model , 2009, Neurobiology of Aging.

[92]  R. Hamilton,et al.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[93]  J. Cummings,et al.  Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. , 2009, Current Alzheimer research.

[94]  Jianhua Shi,et al.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[95]  A. Hofman,et al.  Insulin metabolism and the risk of Alzheimer's disease: The Rotterdam Study , 2009, Alzheimer's & Dementia.

[96]  J. Moriguti,et al.  (Pre)diabetes, brain aging, and cognition. , 2009, Biochimica et biophysica acta.

[97]  George Perry,et al.  The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.

[98]  Kristine Yaffe,et al.  Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. , 2009, JAMA.

[99]  Nick C Fox,et al.  Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.

[100]  K. Weisgraber,et al.  Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure* , 2009, Journal of Biological Chemistry.

[101]  A. Hazell,et al.  Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. , 2009, Alcohol and alcoholism.

[102]  Rachel L. Mistur,et al.  Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease , 2009, Neurology.

[103]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[104]  L. Hanson,et al.  Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease , 2008, BMC Neuroscience.

[105]  Xiongwei Zhu,et al.  Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins , 2008, Proceedings of the National Academy of Sciences.

[106]  Alberto Pupi,et al.  Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease , 2008, Annals of the New York Academy of Sciences.

[107]  U. Tuor,et al.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. , 2008, Brain : a journal of neurology.

[108]  H. Soininen,et al.  Differential Hypometabolism Patterns according to Mild Cognitive Impairment Subtypes , 2008, Dementia and Geriatric Cognitive Disorders.

[109]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[110]  J. Pei,et al.  mTOR-dependent signalling in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[111]  G. McKhann,et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.

[112]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[113]  H. Rusinek,et al.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[114]  Angel Ortega,et al.  Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. , 2008, Free radical biology & medicine.

[115]  Brian Spencer,et al.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.

[116]  Bruce Tidor,et al.  Optimal Drug Cocktail Design: Methods for Targeting Molecular Ensembles and Insights from Theoretical Model Systems , 2008, J. Chem. Inf. Model..

[117]  S. Santi,et al.  Hippocampal hypometabolism predicts cognitive decline from normal aging , 2008, Neurobiology of Aging.

[118]  J. Forbes,et al.  Advanced glycation: implications in tissue damage and disease. , 2008, Protein and peptide letters.

[119]  Elena Salvatore,et al.  In Vivo Imaging of Neurotransmission and Brain Receptors in Dementia , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[120]  J. Born,et al.  Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. , 2008, The Journal of clinical endocrinology and metabolism.

[121]  D. Turner,et al.  NADH hyperoxidation correlates with enhanced susceptibility of aged rats to hypoxia , 2008, Neurobiology of Aging.

[122]  Wen-Lang Lin,et al.  Autophagic‐lysosomal perturbation enhances tau aggregation in transfectants with induced wild‐type tau expression , 2008, The European journal of neuroscience.

[123]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[124]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[125]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[126]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[127]  Yanling Zhao,et al.  Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage , 2008, Neurobiology of Disease.

[128]  G. Bertilsson,et al.  Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease , 2008, Journal of neuroscience research.

[129]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[130]  A. Roses,et al.  Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons , 2008, Proceedings of the National Academy of Sciences.

[131]  I. Grundke‐Iqbal,et al.  Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease , 2008, FEBS letters.

[132]  W. Hoefnagels,et al.  No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial , 2008, PloS one.

[133]  W. Klein,et al.  Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[134]  D. Detel,et al.  The Influence of Age on Intestinal Dipeptidyl Peptidase IV (DPP IV/CD26), Disaccharidases, and Alkaline Phosphatase Enzyme Activity in C57BL/6 Mice , 2007, Experimental aging research.

[135]  J B Poline,et al.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[136]  Christian Hölscher,et al.  Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.

[137]  J. Blass,et al.  Thiamine-dependent processes and treatment strategies in neurodegeneration. , 2007, Antioxidants & redox signaling.

[138]  Angus M. Brown,et al.  Astrocyte glycogen and brain energy metabolism , 2007, Glia.

[139]  P. Magistretti,et al.  Activity‐dependent regulation of energy metabolism by astrocytes: An update , 2007, Glia.

[140]  W. R. Bruce,et al.  A thermolyzed diet increases oxidative stress, plasma alpha-aldehydes and colonic inflammation in the rat. , 2007, Chemico-biological interactions.

[141]  S. Vannucci,et al.  Supply and Demand in Cerebral Energy Metabolism: The Role of Nutrient Transporters , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[142]  J. Buxbaum,et al.  Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.

[143]  G. Gibson,et al.  Changes in inflammatory processes associated with selective vulnerability following mild impairment of oxidative metabolism , 2007, Neurobiology of Disease.

[144]  B. Akıncı,et al.  Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus. , 2007, Diabetes research and clinical practice.

[145]  Marinos C. Dalakas,et al.  β‐Amyloid is a substrate of autophagy in sporadic inclusion body myositis , 2007 .

[146]  B. McEwen,et al.  Corticosterone Impairs Insulin-Stimulated Translocation of GLUT4 in the Rat Hippocampus , 2007, Neuroendocrinology.

[147]  B. Michel,et al.  Effets de l’association de la Sulbutiamine à un inhibiteur de l’acétylcholinestérase dans les formes légères à modérées de la maladie d’Alzheimer , 2007 .

[148]  Richard Kovács,et al.  Mitochondria and neuronal activity. , 2007, American journal of physiology. Cell physiology.

[149]  T. Bliss,et al.  Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation , 2007, The European journal of neuroscience.

[150]  P. Aisen,et al.  A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.

[151]  L. Mucke,et al.  Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.

[152]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[153]  L. Leng,et al.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes , 2006, Diabetologia.

[154]  Luc Pellerin,et al.  Competition between glucose and lactate as oxidative energy substrates in both neurons and astrocytes: a comparative NMR study , 2006, The European journal of neuroscience.

[155]  D. Galati,et al.  Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.

[156]  G. Ramakers,et al.  Insulin signaling in the central nervous system: Learning to survive , 2006, Progress in Neurobiology.

[157]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[158]  D. Chan.  Mitochondria: Dynamic Organelles in Disease, Aging, and Development , 2006, Cell.

[159]  Hideyuki Okano,et al.  Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.

[160]  S. Craft,et al.  Insulin resistance, inflammation, and cognition in Alzheimer's Disease: Lessons for multiple sclerosis , 2006, Journal of the Neurological Sciences.

[161]  Masaaki Komatsu,et al.  Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.

[162]  Xiongwei Zhu,et al.  Therapeutic options in Alzheimer’s disease , 2006, Expert review of neurotherapeutics.

[163]  M. Boustani,et al.  Memantine combined with an acetyl cholinesterase inhibitor – hope for the future? , 2006, Neuropsychiatric disease and treatment.

[164]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[165]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[166]  D. Lonsdale.  A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives , 2006, Evidence-based complementary and alternative medicine : eCAM.

[167]  P. Scheltens,et al.  Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.

[168]  B. Szabó,et al.  The novel β‐secretase inhibitor KMI‐429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wild‐type mice , 2006 .

[169]  P. E. Gold.  Glucose and age-related changes in memory , 2005, Neurobiology of Aging.

[170]  Suzanne Craft,et al.  Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation , 2005, Neurobiology of Aging.

[171]  R. Vassar,et al.  Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[172]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[173]  W. R. Bruce,et al.  The effects of partial thiamin deficiency and oxidative stress (i.e., glyoxal and methylglyoxal) on the levels of α‐oxoaldehyde plasma protein adducts in Fischer 344 rats , 2005, FEBS letters.

[174]  M. Beal,et al.  Mitochondria take center stage in aging and neurodegeneration , 2005, Annals of neurology.

[175]  T. Comery,et al.  Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[176]  B. Winblad,et al.  Levels of mTOR and its downstream targets 4E‐BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain , 2005, The FEBS journal.

[177]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[178]  M. Paccalin,et al.  mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP‐PS1 transgenic models and in patients with Alzheimer's disease , 2005, Journal of neurochemistry.

[179]  A. Convit,et al.  Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.

[180]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[181]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[182]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[183]  Parvesh Bubber,et al.  Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications , 2005, Annals of neurology.

[184]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[185]  L. Nguyễn,et al.  Adult Hypophosphatasia and a Low Level of Red Blood Cell Thiamine Pyrophosphate , 2005, Annals of Nutrition and Metabolism.

[186]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[187]  K. Maiese,et al.  Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease , 2005, Progress in Neurobiology.

[188]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[189]  B. Lamb,et al.  Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. , 2004, The international journal of biochemistry & cell biology.

[190]  S. Melov.  Modeling mitochondrial function in aging neurons , 2004, Trends in Neurosciences.

[191]  P. Dodd,et al.  Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease , 2004, Neurochemistry International.

[192]  Fahmeed Hyder,et al.  Energetic basis of brain activity: implications for neuroimaging , 2004, Trends in Neurosciences.

[193]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[194]  I. Torres-Aleman,et al.  The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. , 2004, European journal of pharmacology.

[195]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[196]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[197]  W. Markesbery,et al.  Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[198]  Ronald C Petersen,et al.  Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.

[199]  Govind Bhagat,et al.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. , 2003, The Journal of clinical investigation.

[200]  W. R. Bruce,et al.  Toxicity of glyoxals--role of oxidative stress, metabolic detoxification and thiamine deficiency. , 2003, Biochemical Society transactions.

[201]  Arnold J. Levine,et al.  Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[202]  G. Small,et al.  Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. , 2003, Molecular Genetics and Metabolism.

[203]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[204]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[205]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[206]  M. Packard,et al.  Systemic or intra‐amygdala injections of glucose facilitate memory consolidation for extinction of drug‐induced conditioned reward , 2003, The European journal of neuroscience.

[207]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[208]  Charles DeCarli,et al.  Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment , 2003, The Lancet Neurology.

[209]  J. Cho,et al.  Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. , 2003, The Journal of biological chemistry.

[210]  K. Någren,et al.  Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[211]  I. Meinertzhagen,et al.  Axonal Transport of Mitochondria to Synapses Depends on Milton, a Novel Drosophila Protein , 2002, Neuron.

[212]  W. Klapper,et al.  Presenilin-1 Mutations Sensitize Neurons to DNA Damage-Induced Death by a Mechanism Involving Perturbed Calcium Homeostasis and Activation of Calpains and Caspase-12 , 2002, Neurobiology of Disease.

[213]  D. Turnbull,et al.  The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease , 2002, Neuropathology and applied neurobiology.

[214]  John R. Fawcett,et al.  Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants , 2002, Brain Research.

[215]  J. Witteman,et al.  Dietary intake of antioxidants and risk of Alzheimer disease. , 2002, JAMA.

[216]  W. Staines,et al.  Immunohistochemical localization and quantification of glucose transporters in the mouse brain , 2002, Neuroscience.

[217]  G. Biessels,et al.  Ageing and diabetes: implications for brain function. , 2002, European journal of pharmacology.

[218]  R. Martins,et al.  Intraneuronal advanced glycation endproducts in presenilin‐1 Alzheimer's disease , 2002, Neuroreport.

[219]  A. Takashima,et al.  Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100 , 2002, Neuroscience Letters.

[220]  A. LeBlanc,et al.  Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons , 2002, The Journal of cell biology.

[221]  W. Markesbery,et al.  Selective loss of KGDHC-enriched neurons in alzheimer temporal cortex , 2001, Journal of Molecular Neuroscience.

[222]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[223]  K. Tominaga-Yoshino,et al.  Neurotoxic and neuroprotective effects of glutamate are enhanced by introduction of amyloid precursor protein cDNA , 2001, Brain Research.

[224]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[225]  D. Rothman,et al.  Measurement of β‐hydroxybutyrate in acute hyperketonemia in human brain , 2001 .

[226]  R. Castellani,et al.  Active glycation in neurofibrillary pathology of Alzheimer disease: Nε-(Carboxymethyl) lysine and hexitol-lysine , 2001 .

[227]  R. Swerdlow,et al.  Functional mitochondria are required for amyloid β‐mediated neurotoxicity , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[228]  P. Greengard,et al.  Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling , 2001, The Journal of Neuroscience.

[229]  R. Duelli,et al.  Brain glucose transporters: relationship to local energy demand. , 2001, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[230]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[231]  Z. Makita,et al.  Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease , 2001, Brain Research.

[232]  R. Bucala,et al.  Neurotoxicity of Advanced Glycation End‐Products for Cultured Cortical Neurons , 2000, Journal of neuropathology and experimental neurology.

[233]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[234]  S. Zabrodskaya,et al.  Antioxidant properties of thiamine , 2000, Bulletin of Experimental Biology and Medicine.

[235]  V. Haroutunian,et al.  Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype , 2000, Annals of neurology.

[236]  Philip Scheltens,et al.  Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias , 2000, Current opinion in neurology.

[237]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[238]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[239]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[240]  M. Mueckler,et al.  Glucose transport and apoptosis , 2000, Apoptosis.

[241]  G. Gibson,et al.  Vascular Endothelium Is a Site of Free Radical Production and Inflammation in Areas of Neuronal Loss in Thiamine‐deficient Brain , 2000, Annals of the New York Academy of Sciences.

[242]  S. O’Keeffe.  Thiamine deficiency in elderly people. , 2000, Age and ageing.

[243]  T. Wilkinson,et al.  Is thiamine deficiency in elderly people related to age or co-morbidity? , 2000, Age and ageing.

[244]  D. Cornblath,et al.  Biobehavioral characteristics of nondemented older adults with subclinical brain atrophy , 2000, Neurology.

[245]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[246]  D. Alkon,et al.  Brain Insulin Receptors and Spatial Memory , 1999, The Journal of Biological Chemistry.

[247]  F. Fazio,et al.  Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[248]  R. L. Russell,et al.  Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. , 1999, Archives of biochemistry and biophysics.

[249]  R. Schliebs,et al.  Insulin‐sensitive GLUT4 glucose transporters are colocalized with GLUT3‐expressing cells and demonstrate a chemically distinct neuron‐specific localization in rat brain , 1999, Journal of neuroscience research.

[250]  C. Parsons,et al.  Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices , 1999, Neuropharmacology.

[251]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[252]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[253]  J. Ávila,et al.  Lithium protects cultured neurons against β‐amyloid‐induced neurodegeneration , 1999 .

[254]  R. Swartz,et al.  ApolipoproteinE and Alzheimer's Disease: a Genetic, Molecular and Neuroimaging Review , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[255]  S. Dimauro,et al.  Mitochondrial involvement in Alzheimer's disease. , 1999, Biochimica et biophysica acta.

[256]  L. Sokoloff.  Energetics of Functional Activation in Neural Tissues , 1999, Neurochemical Research.

[257]  D E Kuhl,et al.  Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. , 1999, Journal of psychiatric research.

[258]  R. Duggleby,et al.  Properties and functions of the thiamin diphosphate dependent enzyme transketolase. , 1998, The international journal of biochemistry & cell biology.

[259]  I. Nonaka,et al.  Accumulation of Tau in Autophagic Vacuoles in Chloroquine Myopathy , 1998, Journal of neuropathology and experimental neurology.

[260]  P. E. Gold,et al.  Memory Modulation Across Neural Systems: Intra-Amygdala Glucose Reverses Deficits Caused by Intraseptal Morphine on a Spatial Task But Not on an Aversive Task , 1998, The Journal of Neuroscience.

[261]  C. Cotman,et al.  Evolution in the Conceptualization of Dementia and Alzheimer’s Disease: Greco-Roman Period to the 1960s , 1998, Neurobiology of Aging.

[262]  R. Hauser,et al.  Plasma Thiamine Deficiency Associated with Alzheimer's Disease but Not Parkinson's Disease , 1998, Metabolic Brain Disease.

[263]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[264]  F. Maxfield,et al.  Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells* , 1997, The Journal of Biological Chemistry.

[265]  G. Shah,et al.  GLUT-1 Expression in the Cerebra of Patients with Alzheimer’s Disease , 1997, Neurobiology of Aging.

[266]  J. Kril,et al.  The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients , 1997, Journal of neurology, neurosurgery, and psychiatry.

[267]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[268]  F. Paoletti,et al.  Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts , 1997, Journal of cellular physiology.

[269]  J. Shoffner.  Oxidative phosphorylation defects and Alzheimer's disease , 1997, Neurogenetics.

[270]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[271]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[272]  S. High,et al.  Interaction of the Thiol-Dependent Reductase ERp57 with Nascent Glycoproteins , 1997, Science.

[273]  S. Barnum,et al.  Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte‐targeted interleukin‐6 expression , 1996, Glia.

[274]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[275]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[276]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.

[277]  S. Kish,et al.  Brain thiamine, its phosphate esters, and its metabolizing enzymes in alzheimer's disease , 1996, Annals of neurology.

[278]  S. Kish,et al.  Brain protein and α‐ketoglutarate dehydrogenase complex activity in alzheimer‐s disease , 1996, Annals of neurology.

[279]  K. Imahori,et al.  Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[280]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[281]  R. Butterworth,et al.  Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease , 1996, Metabolic Brain Disease.

[282]  Y. Mimori,et al.  Thiamine therapy in Alzheimer's disease , 1996, Metabolic Brain Disease.

[283]  W. Engel,et al.  Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[284]  I. Kaneko,et al.  Suppression of Mitochondrial Succinate Dehydrogenase, a Primary Target of β‐Amyloid, and Its Derivative Racemized at Ser Residue , 1995, Journal of neurochemistry.

[285]  E. Roberts,et al.  Age-related alterations in energy metabolism contribute to the increased vulnerability of the aging brain to anoxic damage , 1995, Brain Research.

[286]  S. Horiuchi,et al.  Are advanced glycation end-products associated with amyloidosis in Alzheimer’s disease? , 1995, Neuroreport.

[287]  H. Wiśniewski,et al.  Accumulation of amyloid precursor protein-like immunoreactivity in rat brain in response to thiamine deficiency , 1995, Brain Research.

[288]  G. Rindi,et al.  Intestinal alkaline phosphatase can transphosphorylate thiamin to thiamin monophosphate during intestinal transport in the rat. , 1995, Archives of physiology and biochemistry.

[289]  L. Chang,et al.  Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease , 1995, Neurology.

[290]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[291]  B. Hyman,et al.  Functional Alterations in Alzheimer's Disease: Decreased Glucose Transporter 3 Immunoreactivity in the Perforant Pathway Terminal Zone , 1995, Journal of neuropathology and experimental neurology.

[292]  R J Miller,et al.  Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[293]  Simon Lovestone,et al.  Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells , 1994, Current Biology.

[294]  K. Thai,et al.  Expression of transforming growth factor-β1 during diabetic renal hypertrophy , 1994 .

[295]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[296]  C. Filley,et al.  Electron transport chain defects in Alzheimer's disease brain , 1994, Neurology.

[297]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[298]  W. Honer,et al.  Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease , 1994, Annals of neurology.

[299]  F. Paoletti,et al.  Characteristic transketolase alterations in dermal fibroblasts of Alzheimer patients are modulated by culture conditions. , 1994, Experimental and molecular pathology (Print).

[300]  J. Blass,et al.  Abnormality of the α‐ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease , 1994 .

[301]  H. Nichols,et al.  Thiamin status of the elderly: dietary intake and thiamin pyrophosphate response. , 1994, Journal of the American College of Nutrition.

[302]  K. Meador,et al.  Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type , 1993, Journal of geriatric psychiatry and neurology.

[303]  J. Kril,et al.  Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. , 1993, Alcoholism, clinical and experimental research.

[304]  K. Imahori,et al.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[305]  H. Reichmann,et al.  Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease , 1993, Journal of Neurology.

[306]  J. Cooper,et al.  Mitochondrial function in Alzheimer's disease , 1993, The Lancet.

[307]  G. Cole,et al.  Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.

[308]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[309]  F. Paoletti,et al.  Enhanced proteolytic activities in cultured fibroblasts of Alzheimer patients are revealed by peculiar transketolase alterations , 1991, Journal of the Neurological Sciences.

[310]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[311]  R. Butterworth,et al.  Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease , 1990, Metabolic Brain Disease.

[312]  T. Kuzuya.  [Outline of glucose metabolism and its regulations]. , 1990, Nihon rinsho. Japanese journal of clinical medicine.

[313]  S. Sorbi,et al.  Occurrence of transketolase abnormalities in extracts of foreskin fibroblasts from patients with Alzheimer's disease. , 1990, Biochemical and biophysical research communications.

[314]  R. Mayeux,et al.  Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid , 1990, Neurology.

[315]  P. Mcgeer,et al.  Activation of the classical complement pathway in brain tissue of Alzheimer patients , 1989, Neuroscience Letters.

[316]  Sami I. Horih,et al.  Basic Neurochemistry , 1989, Neurology.

[317]  D. Dorsa,et al.  Insulin and insulin-like growth factors in the CNS , 1988, Trends in Neurosciences.

[318]  J. Blass,et al.  Studies of transketolase abnormality in Alzheimer's disease. , 1988, Archives of neurology.

[319]  J. Blass,et al.  Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. , 1988, Archives of neurology.

[320]  H. Thaler,et al.  Thiamine and Alzheimer's disease. A pilot study. , 1988, Archives of neurology.

[321]  D. Neary,et al.  Mitochondrial function in brain tissue in primary degenerative dementia , 1987, Brain Research.

[322]  R. Butterworth,et al.  Activities of thiamine-dependent enzymes in two experimental models of thiamine deficiency encephalopathy: 3. Transketolase , 1987, Neurochemical Research.

[323]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[324]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[325]  J. Blass,et al.  An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain , 1985, Annals of neurology.

[326]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[327]  R H Huesman,et al.  Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.

[328]  B. Reisberg,et al.  Positron emission tomographic studies of aging and Alzheimer disease. , 1983, AJNR. American journal of neuroradiology.

[329]  S. Sorbi,et al.  Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain , 1983, Annals of neurology.

[330]  E. Perry,et al.  Coenzyme a-acetylating enzymes in Alzheimer's disease: Possible cholinergic ‘compartment’ of pyruvate dehydrogenase , 1980, Neuroscience Letters.

[331]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[332]  M. Brownstein,et al.  Identification of insulin in rat brain. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[333]  C. Phelps,et al.  Barbiturate-induced glycogen accumulation in brain. An electron microscopic study. , 1972, Brain research.

[334]  F. Kauffman,et al.  THE QUANTITATIVE HISTOCHEMISTRY OF ENZYMES OF THE PENTOSE PHOSPHATE PATHWAY IN THE CENTRAL NERVOUS SYSTEM OF THE RAT 1 , 1972, Journal of neurochemistry.

[335]  Hugo Merchant,et al.  Progress in Neurobiology , 2014 .

[336]  S. Subramanian,et al.  Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes. , 2012, Indian journal of experimental biology.

[337]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[338]  Mark A. Smith,et al.  Faculty of 1000 evaluation for Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. , 2012 .

[339]  Michèle Allard,et al.  Brain fuel metabolism, aging, and Alzheimer's disease. , 2011, Nutrition (Burbank, Los Angeles County, Calif.).

[340]  M. Medina.  Recent developments in tau-based therapeutics for neurodegenerative diseases. , 2011, Recent patents on CNS drug discovery.

[341]  S. Hatashita,et al.  Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. , 2010, Journal of Alzheimer's disease : JAD.

[342]  I. Ferreira,et al.  Multiple defects in energy metabolism in Alzheimer's disease. , 2010, Current drug targets.

[343]  G. Perry,et al.  Mitochondrial Dynamics in Alzheimer's Disease Opportunities for Future Treatment Strategies , 2010 .

[344]  松崎 尊信.  Insulin resistance is associated with the pathology of Alzheimer's disease : the Hisayama study , 2010 .

[345]  Nutrition & Metabolism BioMed Central , 2009 .

[346]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[347]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[348]  M. Reger,et al.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.

[349]  A. Erol.  An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[350]  J. Lünemann,et al.  Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. , 2007, Annals of neurology.

[351]  B. Dubois,et al.  [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. , 2007, L'Encephale.

[352]  J. Wands,et al.  Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[353]  N. Zilka,et al.  The tangled story of Alois Alzheimer. , 2006, Bratislavske lekarske listy.

[354]  B. Szabó,et al.  The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. , 2006, Journal of neurochemistry.

[355]  Stavros J. Baloyannis,et al.  Mitochondrial alterations in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[356]  T. Comery,et al.  Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[357]  J. Wands,et al.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.

[358]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[359]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[360]  J. Karlsen,et al.  Kinetics of thiamin and thiamin phosphate esters in human blood, plasma and urine after 50 mg intravenously or orally , 2004, European Journal of Clinical Pharmacology.

[361]  M. Beier.  Drug treatment for Alzheimer's disease. Commentary: Memantine treatment in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. , 2004, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[362]  L. Diep,et al.  Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. , 2004, The journal of nutrition, health & aging.

[363]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[364]  D. Selkoe,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[365]  M. Smith,et al.  Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. , 2001, Free radical biology & medicine.

[366]  R. Hen,et al.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. , 2001, The EMBO journal.

[367]  D. Rothman,et al.  Measurement of beta-hydroxybutyrate in acute hyperketonemia in human brain. , 2001, Journal of neurochemistry.

[368]  L. Mucke,et al.  TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. , 2001, Nature medicine.

[369]  J. Ávila,et al.  Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. , 1999, FEBS letters.

[370]  A. M. Palmer,et al.  The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease , 1999, Journal of Neural Transmission.

[371]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[372]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[373]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[374]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[375]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[376]  K. Thai,et al.  Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. , 1994, Kidney international.

[377]  J. Blass,et al.  Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. , 1994, Annals of neurology.

[378]  J. Langberg,et al.  A trial of thiamine in Alzheimer's disease. , 1991, Archives of neurology.

[379]  O. Tolstykh,et al.  [The role of alpha-tocopherol and thiamine in the correction of lipid peroxidation in compensatory myocardial hypertrophy]. , 1991, Voprosy pitaniia.

[380]  R. Mayeux,et al.  Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. , 1990, Neurology.

[381]  S. Dimauro,et al.  Mitochondrial diseases. , 1989, Neurologic clinics.

[382]  Y. Ihara,et al.  Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. , 1986, Journal of biochemistry.

[383]  R. Baum,et al.  Thiamin--the interaction of aging, alcoholism, and malabsorption in various populations. , 1984, World review of nutrition and dietetics.

[384]  K. Schaller,et al.  Thiamine absorption in the rat. ii. intestinal alkaline phosphatase activity and thiamine absorption from rat small intestine in-vitro and in-vivo. , 1975, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.